Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy

Diabetes Research and Clinical Practice

Volumn 101, Issue 2, 2013, Pages 99-105

  Xu, Qian ^a   Pan, Jianhong ^b   Yu, Jingwen ^c   Liu, Xiaoxia ^a   Liu, Li ^a   Zuo, Xialin ^a   Wu, Ping ^a   Deng, Houliang ^a   Zhang, Jingjing ^a   Ji, Aimin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Combination therapy; Diabetic peripheral neuropathy; Lipoic acid; Meta analysis; Methylcobalamin

Indexed keywords

MECOBALAMIN; THIOCTIC ACID;

CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DIABETIC NEUROPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; MONOTHERAPY; MOTOR NERVE CONDUCTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERONEUS NERVE; REVIEW; SENSORY NERVE CONDUCTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84881263911     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.03.033     Document Type: Review

References (46)

1. Solomon T., Dinesh S. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012, 28(1):8-14.
2. Spruce M.C., Potter J., Coppini D.V. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med 2003, 20:88-98.
3. UKPDS Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
4. Ziegler D. Treatment of diabetic polyneuropathy update 2006. Ann N Y Acad Sci 2006, 1084:250-266.
5. Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabet Care 2010, 33(10):2285-2293.
6. Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysis. Diabet Med 2004, 21:114-121.
7. Han T.T., Bai J.F., Liu W., Hu Y.M. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012, 167:465-471.
8. Zhang Y.F., Ning G. Mecobalamin. Expert Opin Investig Drugs 2008, 17(6):953-964.
9. Kathleen A., Head N.D. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006, 11(4):294-329.
10. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
11. David M., Pham B., Alison J., Deborah J.C., Alejandro R.J., Michael M., et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998, 22(8). 352(9128):609-13.
12. Zhao Y.Y., Li H., Fang Z.Y., Ma J., Hu B. Combined therapeutic effects of α-lipoic acid and mecobalamin on diabetic peripheral neuropathy. J Pract Med 2008, 24(24):4289-4290.
13. Zhang X.L., Feng Y.L., Zhou B.A., Wei G.Y. Effects of mecobalamin and α-lipoic acid on diabetic peripheral neuropathy. Shandong Med J 2009, 49(7):48-49.
14. Suo L.N., Zhang D. Effects of lipoic acid and mecobalamin on diabetic peripheral neuropathy. J Tradit Chin Med 2009, 24(6):1104-1105.
15. Li H.J. Effects of α-lipoic acid and mecobalamin on diabetic peripheral neuropathy. Chin J Misdiag 2008, 8(36):8847-8848.
16. Zhang C., Yu X.J., Shi W.W. Combined therapeutic effects of α-lipoic acid and mecobalamin on diabetic peripheral neuropathy. Heilongjiang Med Pharm 2009, 32(6):78-79.
17. Xin Y.Y. Effects of α-lipoic acid on diabetic peripheral neuropathy. China Modern Doctor 2009, 49(34):45-49.
18. Jia Z.M. Combined therapeutic effects of α-lipoic acid and mecobalamin on diabetic peripheral neuropathy. Chin J Mod Drug Appl 2010, 13(4):143-144.
19. Zhao Y.H., Li H., Fang Z.Y., Ma J., Hu P. Effects of lipoic acid combined with mecobalamin on diabetic peripheral neuropathy. China Modern Doctor 2011, 49(35):56-57.
20. Wang Z.H., Yang X.J., Fan F. Effects of lipoic acid combined with mecobalamin on diabetic peripheral neuropathy. J Pract Med 2011, 18(8):863-864.
21. Zhu Y.P., Zhang H. Effects of lipoic acid combined with mecobalamin on DPN. Med Inform 2011, 24(8):24-25.
22. Luo S.J. Effects of lipoic acid combined with mecobalamin on diabetic peripheral neuropathy. Modern J Integr Tradit Chin Western Med 2011, 20(3):303-304.
23. Song X.C., Ling G.M., Xie Q.P. Therapeutic effect of lipoic acid on diabetic peripheral neuropathy based on 84 cases clinical observation. Intern Med 2011, 6(5):413-415.
24. Gao A.R., Zhang X.H. Clinical value study of α-lipoic acid combined with Mecobalamin in treating Diabetic Peripheral Neuropathy. Chin Remed Clin 2011, 11(12):1452-1453.
25. Lin Y.L., Zhong R.F. Effects of Mecobalamin and α-lipoic acid on diabetic peripheral neuropathy. China Modern Doctor 2012, 19(12):53-54.
26. Yang Y., Song X.H., Liu J.Y., Qu B. Clinical value study of α-lipoic acid combined with Mecobalamin in treating Diabetic Peripheral Neuropathy. China Medical Herald 2012, 9(8):86-87.
27. Cui F.Y., Shi Z.D. Clinical value study of α-lipoic acid combined with Mecobalamin in treating Diabetic Peripheral Neuropathy. Chin J Pract Med 2012, 39(9):107-108.
28. Zhang R.Q. Clinical value study of lipoic acid in treating Diabetic Peripheral Neuropathy. Clin Med China 2012, 28(6):614-616.
29. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabet Res Clin Pract 2011, 94:311-321.
30. Li N.J. From Kingdom to Kingdom, but hopefully not again. Diabet Res Clin Pract 2012, 10:1-2.
31. Dyck P.J., KarnesJL, O'Brian P.C. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992, 42:1164-1170.
32. Eichberg J. Protein kinase C changes in diabetes: is the concept relevant to neuropathy?. Int Rev Neurobiol 2002, 50:61-82.
33. Cameron N.E., Cotter M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997, 46:S31-S37.
34. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994, 94:853-859.
35. Ambrosch A., Dierkes J., Lobmann R. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabet Med 2001, 18:185-192.
36. Nagamatsu M., Nickander K.K., Schmelzer J.D., Raya A., Wittrock D.A., Tritschler H. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabet Care 1995, 18:1160-1167.
37. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Lund D.D., Yorek M.A. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001, 50:1927-1937.
38. Kunt T., Forst T., Wilhelm A., Tritschler H., Pfuetzner A., Beyer J. a-Lipoic acid reduces expression of vascular cell adhadhesion of human monocytes after stimulation with advanced glycation end products. Clin Sci 1999, 96:75-82.
39. Sola S., Mir M.Q., Cheema F.A., Khan-Merchant N., Menon R.G., Khan B.V. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005, 111:343-348.
40. Kishi Y., Schmelzer J.D., Yao J.K. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 1999, 48:2045-2051.
41. Stevens M.J., Obrosova I., Cao X. Effects of dl-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000, 49:1006-1015.
42. Heitzer T., Finckh B., Albers S., Krohn K., Kohlschutter A., Meinertz T. Beneficial effects of a-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001, 31:53-61.
43. Li N.J. From Kingdom to Kingdom, but hopefully not again. Diabetes Res Clin Pract 2012, 1-2.
44. Kuwabara S., Nakazawa R., Azuma N., Suzuki M., Miyajima K., Fuku T. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med 1999, 38:472-475.
45. Sun Y., Lai S., Lu C.J. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan 2005, 14:48-54.
46. Mizukami H., Ogasawara S., Yamagishi S., Takahashi K., Yagihashi S. Methylcobalamin effects on diabetic neuropathy and nerve protein kinase C in rats. Eur J Clin Invest 2011, 41(4):442-450.